Phase 2 N=41 Improving SCI Rehabilitation Interventions by Retraining the Brain
Cervical Spinal Cord Injruy
Primary: Change in Upper Extremity Motor Score (UEMS) With Manual Muscle Testing — 3.5; 2.55 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=177 AI-Powered Fall Risk Prediction in Nursing Care
Accidental Falls · Risk Assessment · Nursing Assessment
Primary: Fall Risk Categories Based on the Morse Fall Scale — 131; 41; 5 Participants
Phase 3 N=241 A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Sickle Cell Disease · Vaso-occlusive Pain Episode in Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Rate of Vaso-occlusive Crises (VOCs) [Adjudicated] Through Week 48 — 1.49; 1.58 Events per 48 weeks — p=0.6967
N/A N=46 Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome
Dysbiosis · Endotoxemia · Metabolic Syndrome
Primary: Serum Endotoxin — 31.6; 26.7; 44.5; 39.1 EU/mL
N/A N=295 POLARx™ Cardiac Cryoablation System Post Market Clinical Study (POLAR SMART)
Paroxysmal Atrial Fibrillation
Primary: Safety Event Free Rate — 285 Participants
N/A N=235 Education for Prevention and Treatment of Frailty
Frailty · Frail Elderly Syndrome
Primary: Evaluation of the Change of Baseline Fried Frailty Criteria at 6 Months — 2.3; 1.4 scores on a scale
N/A N=36,104 Mental Health Associations With Vitiligo
Vitiligo · Depressive Episode · Recurrent Depressive Disorder
Primary: Number of Participants With Depressive Episodes — 1018; 4007 Participants
N/A N=30 The R4R Advance Care Planning Pilot Study
Advance Care Planning
Primary: Advance Care Planning Values/Beliefs — 24.9; 26.3 Score on a scale
N/A N=95 Assessing the Feasibility of Economic Approaches to Prevent Substance Abuse Among Adolescents
Adolescent Drinking · HIV/AIDS · Drug Use
Primary: Percentage of Participants Completing the Study at 6 Months — 44; 46 Participants
Phase 3 N=62 Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
Tendinopathy
Primary: Change From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 24 — 55.7; 46.8 Score on a Scale
Phase 1 N=16 A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
Healthy
Primary: Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC₀-∞) — 28100; 31200; 37300 Hours × picomoles…
N/A N=30 IMAS Optimization and Applicability in Acute and Subacute Stroke.
Acute Stroke
Primary: Coefficient of Determination (R²) for Predicting Fugl-Meyer Upper Extremity Score Recovery Post-stroke. — 0.9 Coefficient of determination (Unitless)
N/A N=48 Kindergarten Children Acquiring Words Through Storybook Reading
Language Development Disorders
Primary: Change in Definition Scores From Pre- to 12-weeks Post-treatment — 2.50; 3.18; 5.50 number of words
N/A N=20 DadSpace: Increasing Community Support Resources for Perinatal Fathers
Paternal Behavior · Father-Child Relations · Family Relations
Primary: Change in Knowledge of Infant Development Inventory — 77.78; 81.87; 67.25; 78.95 Percent correct
Phase 1 N=14 A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 9597.74; 9786.78 hour *…